Clinical transplantation · 2026
Cancer Risk After Simultaneous Pancreas-Kidney Transplantation Compared With Kidney Transplant Alone: A Propensity-Matched Cohort Study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Balloura Mohamad Amir, Mawaldi Mohammad, Johnson Brittany, Ovincy Cene, Fontanez Nicole Camacho, Ingram Demarcus, Me Hay Me, Leeaphorn Napat, Attieh Rose Mary
Аннотация
BACKGROUND: Post-transplant malignancy is a major determinant of long-term outcomes after solid organ transplantation. Whether simultaneous pancreas-kidney (SPK) transplantation confers a differential post-transplant cancer risk compared With kidney transplantation alone (KA) remains uncertain.
METHODS: We conducted a retrospective propensity score-matched cohort study of adult transplant recipients at three Mayo Clinic sites between 2001 and 2017. SPK recipients (n = 484) were matched 1:1 with KA recipients using propensity scores. The primary outcome was post-transplant cancer incidence analyzed using Fine-Gray competing risks regression with death as a competing event. Standardized incidence ratios (SIRs) were calculated relative to the US general population. Cox proportional hazards models with cancer modeled as a time-varying covariate evaluated associations with mortality and death-censored graft failure.
RESULTS: Over a median follow-up of 10 years, overall cancer incidence was similar between SPK and KA recipients (subdistribution hazard ratio [sHR] 0.80, 95% CI 0.63-1.02; p = 0.07). The observed trend toward lower cancer incidence in SPK recipients was driven by a lower incidence of non-melanoma skin cancer (NMSC) (sHR 0.72, 95% CI 0.53-0.97; p = 0.03), which was attenuated after age adjustment (sHR 0.76, p = 0.07). Incidence of other malignancies did not differ between groups. Compared with the US general population, cancer risk excluding NMSC was approximately twofold higher in both cohorts (SIR 2.18 for SPK vs. 2.23 for KA). Incident malignancy was strongly associated with increased mortality (HR 3.40 in KA and 2.07 in SPK) but not with a statistically significant increase in graft failure.
CONCLUSIONS: In this propensity score-matched cohort study, overall post-transplant malignancy incidence was comparable between SPK and KA recipients. Both groups experienced substantially elevated cancer risk relative to the general population, and incident malignancy was strongly associated with mortality. These findings suggest that malignancy risk is driven primarily by shared immunologic and demographic factors rather than transplant type.
METHODS: We conducted a retrospective propensity score-matched cohort study of adult transplant recipients at three Mayo Clinic sites between 2001 and 2017. SPK recipients (n = 484) were matched 1:1 with KA recipients using propensity scores. The primary outcome was post-transplant cancer incidence analyzed using Fine-Gray competing risks regression with death as a competing event. Standardized incidence ratios (SIRs) were calculated relative to the US general population. Cox proportional hazards models with cancer modeled as a time-varying covariate evaluated associations with mortality and death-censored graft failure.
RESULTS: Over a median follow-up of 10 years, overall cancer incidence was similar between SPK and KA recipients (subdistribution hazard ratio [sHR] 0.80, 95% CI 0.63-1.02; p = 0.07). The observed trend toward lower cancer incidence in SPK recipients was driven by a lower incidence of non-melanoma skin cancer (NMSC) (sHR 0.72, 95% CI 0.53-0.97; p = 0.03), which was attenuated after age adjustment (sHR 0.76, p = 0.07). Incidence of other malignancies did not differ between groups. Compared with the US general population, cancer risk excluding NMSC was approximately twofold higher in both cohorts (SIR 2.18 for SPK vs. 2.23 for KA). Incident malignancy was strongly associated with increased mortality (HR 3.40 in KA and 2.07 in SPK) but not with a statistically significant increase in graft failure.
CONCLUSIONS: In this propensity score-matched cohort study, overall post-transplant malignancy incidence was comparable between SPK and KA recipients. Both groups experienced substantially elevated cancer risk relative to the general population, and incident malignancy was strongly associated with mortality. These findings suggest that malignancy risk is driven primarily by shared immunologic and demographic factors rather than transplant type.